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Background: To determine the psychometric properties and minimal clinically important differences (MCIDs) of the
World Health Organization Quality of Life-BREF (WHOQOL-BREF) in advanced stage lung cancer patients.
Methods: Patients (n = 153) completed the WHOQOL-BREF and the European Organisation for Research and Treatment
of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Confirmatory factor analysis (CFA) was performed and
reliability and construct validity determined. MCIDs were estimated with two distribution-based methods (0.5 standard
deviation (SD) and 1 standard error of measurement (1 SEM)).
Results: CFA confirmed WHOQOL-BREF domain structure. All domains demonstrated good internal consistency (α> 0.70),
except Social Relationships (α = 0.57). Nineteen of the 24 WHOQOL-BREF items had correlations of ≥ 0.40 with
their intended domain. Four items had higher correlations with a domain other than their intended domain.
Moderate to strong correlations were observed for corresponding domains of the two questionnaires, except
for the social domains (r = 0.07). For 0.5 SD, MCIDs ranged from 0.88 to 1.55, and for 1 SEM MCIDs ranged from
1.76 to 2.72.
Conclusions: The WHOQOL-BREF has satisfactory psychometric properties in patients with advanced stage lung cancer,
whereas the observed MCIDs provide a method for interpretation of scores.
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In general, chemotherapy in patients with advanced dis-
ease lung cancer is associated with small survival bene-
fits [1, 2]. In addition, Quality of Life (QoL) may be
reduced in patients with lung cancer [3]. This empha-
sizes the importance of maintaining patients’ Quality of
Life (QoL) at an acceptable level by early identification
of treatment-induced changes. QoL is evaluated by ques-
tionnaires of which the European Organisation for Re-
search and Treatment of Cancer Quality of Life-Core 30
questionnaire (EORTC QLQ-C30) is one of the most fre-
quently applied in cancer [4]. However, this instrument is
considered to be a Health Related Quality of Life (HRQoL)
questionnaire (i.e. it focusses on those aspects of QoL re-
lated to the disease and its treatment) and measures to a
lesser extent patients’ opinions of the other aspects of
QoL [4]. Therefore, the WHO formulated a compre-
hensive definition of QoL based on extensive research.
In 2004, they released the World Health Organization
Quality of Life instrument-BREF (WHOQOL-BREF) to
enable rapid QoL assessment in epidemiological sur-
veys and clinical studies [5].
Recently, a study performed in Taiwanese patients diag-
nosed with stage I to IV lung cancer reported satisfactory
psychometric properties of the WHOQOL-BREF. However,
the 28-item Taiwanese version of the WHOQOL-BREF
(the original WHOQOL-BREF holds 26 items [5]) was used
and specific results concerning patients with advanced dis-
ease lung cancer were not reported. Therefore, further psy-
chometric validation of the WHOQOL-BREF in this group
may be mandatory for several reasons. First, patients with
advanced lung cancer form a well-defined group due to
their poor prognosis compared to patients with stage I or II
lung cancer and the population in the WHOQOL-BREF
field trial [5]. Second, apart from the symptoms of lung
cancer, treatment is in most patients with advanced disease
lung cancer associated with substantial adverse events
which can directly influence (HR) QoL. Third, although
some studies have reported results of the WHOQOL-BREF
in lung cancer [6, 7], the application of this questionnaire in
patients starting treatment with chemotherapy was not re-
ported. Fourth, as correct interpretation of the minimal
clinically important difference (MCID) depends on the psy-
chometric characteristics of the instrument and the patient
population from which it is derived, the determination of a
reliable MCID in lung cancer ideally requires evaluation of
the reliability and validity of the WHOQOL-BREF in these
patients.
Given these considerations, additional research is needed
to enable implementation of the WHOQOL-BREF in fu-
ture trials investigating therapeutic regimens in lung cancer
and to facilitate the interpretation of individual scores. To
contribute to these goals the objective of our study focused
on two main aspects of the WHOQOL-BREF: (1) to testthe reliability and validity of the WHOQOL-BREF in pa-
tients with advanced disease lung cancer, and (2) to assess
the MCIDs of the WHOQOL-BREF domain scores.
We expected that the 4-domain structure of the
WHOQOL-BREF would be confirmed and that the internal
consistencies of all domains were at least acceptable, except
for Social Relationships [5]. Moreover, we hypothesized that
all items of the WHOQOL-BREF would have an acceptable
positive correlation (i.e. correlation coefficient ≥ 0.40) with
their intended domains and that all items would have
higher positive correlations with their intended domain
than with the other three domains [8]. Considering con-
struct validity, we expected significant differences in mean
domain scores between known groups according to ECOG
performance score and EORTC QLQ-C30 Global Health
Status/QoL score [9]. In addition, construct validity was
assessed by correlating the domains of the WHOQOL-
BREF with the scales of the EORTC QLQ-C30 [9]. We hy-
pothesized that all domains would have at least moderate
correlations (i.e. correlation coefficient ≥ 0.50) with their
corresponding scales of the EORTC QLQ-C30 [10]. In this
study, we expected no floor or ceiling effects for domain
scores of the WHOQOL-BREF.
Methods
Study population
PERSONAL is a prospective observational multi-center
cohort study of patients with non-squamous non-small
cell lung carcinoma (NSCLC) and unresectable mesotheli-
oma receiving pemetrexed. Patients were recruited from
October 2012 to November 2014 from three teaching hos-
pitals (Erasmus University Medical Center, Amphia Hos-
pital and Sint Franciscus Gasthuis hospital) and a regional
hospital (Bravis hospital) in the Netherlands. For this
study, which is part of an ongoing analysis of PERSONAL,
data of 191 enrolled patients was available. Patients were
enrolled if they met the following criteria: were aged 18
years or older, had a cytological or histological confirmed
diagnosis of non-squamous NSCLC or unresectable ma-
lignant pleural mesothelioma and started treatment with
pemetrexed monotherapy or in combination with a plat-
inum compound. Patients were excluded when they were
not able to read Dutch or could not complete the ques-
tionnaires because of a physical or mental condition. A
sample size of at least 50 patients was needed in order to
perform a validation study [9]. Informed consent was ob-
tained from all individual participants included in the
study. This multi-center study was approved by the Insti-
tutional Review Board of the Erasmus University Medical
Center in Rotterdam, the Netherlands.
Study measures
The WHOQOL-BREF [5, 11] is a well-established generic
QoL instrument intended for use in a wide range of chronic
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four domains plus two items of the General Facet describ-
ing Overall QoL and General Health. The domains repre-
sent Physical Health (seven items), Psychological Health
(six items), Social Relationships (three items), and Environ-
ment (eight items) and are scored on a 4–20 scale with
higher scores indicating a better QoL [11]. The General
Facet is scored on a 2–10 scale. Previous studies have dem-
onstrated good psychometric properties of the WHOQOL-
BREF in patients with lung cancer [12] and in patients with
chronic diseases or different forms of cancer [5].
The EORTC QLQ-C30 is a cancer-specific HRQoL
instrument with demonstrated psychometric properties
[13]. It consists of 30 items and incorporates a Global
Health Status/QoL scale, five functional scales and several
single items assessing additional symptoms or problems.
The functional scales represent Physical Functioning (five
items), Cognitive Functioning (two items), Emotional
Functioning (four items), Role Functioning (two items),
and Social Functioning (two items). EORTC QLQ-C30
scales are scored on a 0–100 scale, with higher scores on
the functional scales being indicative of better HRQoL,
whereas higher scores on the symptom scales are reflect-
ive of worse symptoms [4].
All questionnaires were completed after diagnosis and
before the first cycle of chemotherapy. In addition to
completing the questionnaires, we collected sociodemo-
graphic information (i.e. age, gender, educational level,
ethnicity, employment, partner status) and clinical infor-
mation (i.e. cancer stage, type of tumour, line of therapy
and the Eastern Cooperative Oncology Group (ECOG)
performance status). At day 1 of the first cycle of chemo-
therapy we assessed, according to Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0, the
severity and number of different cancer related and, if
applicable, treatment related adverse events that patients
experienced.
Statistical analysis
The response distributions of item and domain scores of
the WHOQOL-BREF were assessed by using two
methods. As proposed in the validation paper of the
WHOQOL-BREF, skewness was observed if less than
10% of responses fell in each of two adjacent scale points
of an item at the extreme ends of the scale [5]. Floor and
ceiling effects of domain scores of the WHOQOL-BREF
were considered to be present if more than 15% of the re-
spondents achieved the lowest (i.e. floor effect) or highest
(i.e. ceiling effect) possible score [9].
The multi-trait/multi-method methodology, as pro-
posed by Campbell and Fiske [14] and later adapted by
Ware et al., was used to study item-domain relations [15].
Analyses were performed with MAP-R software which ex-
amines the correlations between items and domains andcorrects the correlation of each item with its intended do-
main for overlap [15]. For the multi-trait/multi-item ana-
lyses, missing values are replaced by the mean score of the
other items of the corresponding domain if at least half of
the items are completed.
According to Trask et al., item-convergent validity was
defined as a correlation coefficient ≥ 0.40 between question-
naire items and their intended domains [8]. Item-divergent
validity was supported when items had higher correlations
with their intended domain than with other domains of the
questionnaire [8].
Construct validity was evaluated by correlating the
WHOQOL-BREF domains with the corresponding scales
of the EORTC QLQ-C30 using Pearson’s correlation coef-
ficient. According to Hinkle, correlations of 0.00 to 0.30
were regarded as negligible, 0.30 to 0.50 as low, 0.50 to
0.70 as moderate, 070 to 0.90 as high, and correlations of
0.90 to 1.00 as very high [10]. In addition, known-groups
validity comparisons were made for the WHOQOL-BREF
domains in relation to the total number of different ad-
verse events, the number of different grade 3 or 4 adverse
events, the ECOG performance status and the Global
Health Status/QoL score of the EORTC QLQ-C30 to as-
sess construct validity. One-way ANOVA was used to de-
termine whether there were any significant differences
between the means of the groups.
Internal consistency reflects the capability of items
within a domain to measure the same concept. To evalu-
ate internal consistency, first the four-factor design of the
WHOQOL-BREF was analysed with confirmatory factor
analysis (CFA) using structural equation modelling. Miss-
ing values were replaced by expectation-maximization
imputation for the CFA. The original model is demon-
strated in Fig. 1. Goodness of fit was assessed by the
Comparative Fit Index (CFI) and the Root Mean
Square Error Approximation (RMSEA). A satisfactory
to good fit is defined when CFI > 0.90 and RMSEA
< 0.06 [16, 17]. For the resulting domains, Cron-
bach’s coefficient alpha was calculated to express in-
ternal consistency. A coefficient of 0.70 or higher
was considered to be acceptable [9].
For each WHOQOL-BREF domain, the MCID was cal-
culated using two distribution-based methods (i.e., the 0.5
SD [18] and 1 standard error of measure (SEM) [19–21]).
MCID is the smallest change in an outcome that a patient
would identify as important. The 0.5 SD benchmark of an
outcome measure means that patients improving more
than 0.5 of the outcome score’s SD have reached a
minimal clinically important difference [22]. As we lacked
a test-retest reliability coefficient, we used the conservative
lower bound of the 95% confidence intervals of the Cron-
bach’s alphas of the four domains to calculate the SEM.
Thus, the SEM was calculated with an altered version of
the SEM formula [23]: SD x √(2× (1 – lower bound 95%
Fig. 1 Four factor model of the WHOQOL-BREF. Abbreviations: WHOQOL-BREF, World Health Organization Quality of Life questionnaire
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p < 0.05 was considered to be statistically significant.
Analyses were performed using SPSS version 21.0,
except for the CFA (AMOS version 22.0) and the cal-
culation of the 95% confidence intervals of the four
domains of the WHOQOL-BREF (R, version 3.2.5).
Results
Patient characteristics
Of the 191 enrolled patients, 153 patients (80.1%) com-
pleted the questionnaires to a sufficient degree. Table 1
summarizes the patient characteristics of these patients.Mean scores, floor and ceiling effects, and skewness
The WHOQOL-BREF domain scores are shown in
Table 2. The mean General Facet score was 5.9 (1.8).
Mean scores of the four domains ranged from 12.9 (SD
3.1; Physical Health) to 16.2 (SD 2.6; Social Relation-
ships). Floor and ceiling effects of the domain scores
were below the limit of 15%. Fourteen of the 26 items
demonstrated skewed response distributions with re-
sponses < 10% in each of two adjacent scale points at
the extreme lower end of the scale indicating that most
of the information was distributed over the other scale
points (Table 2). These items were Positive Feelings,
Table 1 Characteristics of study population
Characteristic Overall sample (n = 153)
Age, years
Mean (SD) 63.4 (9.2)
Min, max 37, 83
Sex
Male 83 (54.2)
Ethnicity
White/Caucasian 143 (93.5)
Asian 3 (2.0)
Negroid 2 (1.3)
Other 5 (3.3)
Educationa
Low 113 (73.9)
High 33 (21.6)
Unknown 7 (4.6)
Employment
Yes 40 (26.1)
No 112 (73.2)
Unknown 1 (0.7)
Partner status
Married/cohabiting 116 (75.8)
Unmarried partners/not cohabiting 6 (3.9)
Divorced/separated 14 (9.2)
Widowed/partner died 10 (6.5)
Single 6 (3.9)
Unknown 1 (0.7)
Cancer stageb
Locally advanced (IIIB) 19 (12.4)
Metastatic (IV) 119 (77.8)
Other 14 (9.2)
Unknown 1 (0.7)
Type of tumorb
Adenocarcinoma 141 (92.2)
Large cell carcinoma 4 (2.6)
Mesothelioma 7 (4.6)
Large cell neuroendocrine carcinoma 1 (0.7)
Line of therapy
First line 134 (87.6)
Second line 10 (6.5)
Third line 1 (0.7)
Adjuvant 8 (5.2)
ECOG performance statusa
Grade 0 39 (25.5)
Grade 1 99 (64.7)
Grade 2 11 (7.2)
Table 1 Characteristics of study population (Continued)
Characteristic Overall sample (n = 153)
Grade 3 2 (1.3)
Unknown 2 (1.3)
Abbreviations: n number of patients, SD standard deviation, ECOG Eastern
Cooperative Oncology Group
Values are given in numbers (percentages) unless stated otherwise
aLow education: persons whose highest level of education is primary
education, lower general education or lower vocational education. High
education: persons whose highest level of education is higher general
education, higher vocational education or university
bMeasured at baseline
de Mol et al. BMC Cancer         (2018) 18:1173 Page 5 of 12Spirituality, Cognitions, Self-esteem, and Body Image for
the Psychological Health domain and Personal Relations
and Social Support for the Social Relationships domain.
In addition, all items of the Environment domain, except
Leisure, demonstrated few responses at the extreme
lower end of the scale. One item, Negative Feelings
exhibited responses < 10% in each of two adjacent scale
points at the extreme upper end of its scale.Confirmatory factor analysis
CFA with the use of structural equation modelling was
conducted to analyse the four-factor structure of the
WHOQOL-BREF. Inspection of the modification indices
revealed two possible modifications to improve the
model fit of the original model. After adding error
covariances between the measurement error of the items
1 (Pain) and 2 (Medication) and between 8 (Positive
Feelings) and 9 (Spirituality) model fit improved. The
CFI increased from 0.854 to 0.896 whereas the RMSEA
decreased from 0.069 to 0.058 approaching both of the
criteria for a satisfactory to good fit (CFI > 0.90 and
RMSEA < 0.06).Multi-trait/multi-item analyses and internal consistency
Multi-trait/multi-item analyses demonstrated that all
items, except those representing Sleep, Body Image, Sex,
Physical Environment, and Finance had a correlation of
≥ 0.40 with their intended domain (Table 3). Four items
showed higher correlations with other domains than
their own. The item Sleep of the Physical Health domain
had a higher positive correlation with the Psychological
Health domain, whereas the items Body Image and
Self-esteem of the Psychological Health domain had
higher positive correlations with the Environment do-
main and the Physical Health domain respectively. In
addition, the item Personal Relationships of the Social
Relationships domain showed a higher positive correl-
ation with the Environment domain than its intended
domain. For all domains, except the Social Relationships
domain, Cronbach’s alpha was higher than 0.70 (i.e.
Physical Health: 0.81, 95% CI 0.76–0.85; Psychological
Health: 0.77, 95% CI 0.71–0.83; Environment: 0.77, 95%
Table 2 Frequency responses for items of the WHOQOL-BREF
Items/
domains
Description n Mean
(SD)
Floor
effect (%)
Ceiling
effect (%)
Scale pointsa
1 2 3 4 5
General facet
Overall QoL 150 5.9 (1.8) 4 (2.7) 3 (2.0) 3.3 14.4 24.2 44.4 12.4
General Health 21.6 35.9 26.1 13.1 2.6
Physical Health
3 Pain 153 12.9 (3.1) 1 (0.7) 1 (0.7) 28.1 28.8 19.0 20.3 3.3
4 Medication 11.8 26.8 25.5 24.8 10.5
10 Energy 3.9 19.6 35.9 25.5 14.4
15 Sleep 8.5 23.5 26.1 26.1 15.0
16 Activities 7.8 34.6 24.8 26.8 5.9
17 Work 12.4 39.2 21.6 20.3 6.5
25 Mobility 4.6 11.8 13.1 35.3 35.3
Psychological Health
5 Positive feelings 153 14.4 (2.5) 0 (0.0) 2 (1.3) 3.9 7.8 39.2 41.2 7.8
6 Spirituality 2.6 5.2 32.7 43.8 15.0
7 Cognitions 4.6 9.8 44.4 22.2 19.0
11 Body image 0.7 4.6 28.1 26.1 39.9
18 Self esteem 0.7 9.8 30.7 43.8 13.7
26 Negative feelings 14.4 32.7 43.1 9.8 0.0
Social Relationships
19 Personal relations 153 16.2 (2.6) 0 (0.0) 20 (13.1) 0.7 0.7 6.5 40.5 50.3
20 Sex 5.9 13.7 36.6 24.8 16.3
21 Social support 0.7 1.3 9.2 34.0 54.9
Environment
8 Safety & security 153 15.9 (2.3) 0 (0.0) 1 (0.7) 0.7 3.9 26.8 32.0 36.6
9 Physical environment 0.7 2.0 26.8 35.3 34.0
12 Finance 2.0 6.5 37.3 21.6 32.0
13 Information 0.0 0.7 36.6 37.3 24.8
14 Leisure 3.9 13.1 24.2 35.3 23.5
22 Home environment 2.6 5.2 12.4 39.9 39.9
23 Health/social care 1.3 2.0 15.7 49.0 32.0
24 Transport 1.3 2.0 9.2 43.8 43.8
Abbreviations: WHOQOL-BREF World Health Organization Quality of Life-BREF questionnaire, n number of patients, SD standard deviation, QoL quality of life
aValues are given in percentages
Values in bold represent skewed distributions of the frequency of responses of patients
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0.68).
Construct validity
Table 4 presents the correlations between the domains
of the WHOQOL-BREF and the EORTC QLQ-C30
domains/symptom scales. In general, low correlations
were observed between WHOQOL-BREF domains and
EORTC QLQ-C30 domains/symptom scales. Only for
Physical Health, moderate to high correlations were ob-
served with the EORTC QLQ-C30 domains except forthe correlation with Cognitive Functioning. The lowest cor-
relations were found between Social Relationships and the
EORTC QLQ-C30 domains/symptom scales. The observed
negative correlations between the WHOQOL-BREF and
EORTC QLQ-C30 symptom scales indicate that a higher
score of the WHOQOL-BREF domains corresponded with
less worse symptoms.
Table 5 shows the known-groups validity comparisons
for the WHOQOL-BREF domains and General Facet in
relation to the number of different adverse events, the
number of different grade 3 or 4 adverse events, the
Table 3 Multi-trait/Multi-item item-domain correlation for the WHOQOL-BREF (n = 153)
Items/domains Description Physical Health Psychological Health Social Relationships Environment
Physical Health
3R Pain .53a .41 .20 .35
4R Medication .40a .24 .01 .21
10 Energy .57a .53 .13 .42
15 Sleep .27a .32 .06 .27
16 Activities .72a .56 .17 .46
17 Work .70a .54 .17 .43
25 Mobility .61a .47 .24 .45
Psychological Health
5 Positive feelings .52 .67a .33 .47
6 Spirituality .34 .53a .24 .36
7 Cognitions .44 .48a .20 .48
11 Body image .32 .34a .30 .45
18 Self esteem .60 .58a .38 .49
26R Negative feelings .43 .52a .21 .43
Social Relationships
19 Personal relations .16 .30 .43a .47
20 Sex .15 .31 .32a .31
21 Social support .16 .28 .43a .42
Environment
8 Safety & security .46 .57 .36 .60a
9 Physical environment .12 .35 .31 .38a
12 Finance .23 .29 .26 .30a
13 Information .24 .33 .36 .53a
14 Leisure .41 .34 .19 .46a
22 Home environment .46 .55 .41 .56a
23 Health/social care .36 .41 .32 .41a
24 Transport .39 .44 .43 .57a
Abbreviations: SD standard deviation, n number of patients, QoL Quality of Life, WHOQOL-BREF World Health Organization Quality of Life-BREF questionnaire
aPearson item-scale correlations corrected for overlap
Correlations in bold represent correlations between items and domains that differ more than two standard errors from their correlations with their own domains
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QoL score. Significant differences were detected regarding
the General Facet score, Physical Health, and Psychological
Health among ECOG grades 0, 1, and 2 or higher. Similar
results were observed for the General Facet and the
WHOQOL-BREF domain scores according to Global
Health Status/QoL as measured by the EORTC QLQ-C30
except for Social Relationships. For all of the observed sig-
nificant differences except one (i.e. Psychological Health
based on ECOG performance score), effect sizes were
medium to large.
Minimal clinically important differences
Table 6 demonstrates the distribution-based esti-
mates of the MCIDs for the different domains of the
WHOQOL-BREF.Discussion
Patients with advanced disease lung cancer are prone to
a decrease in QoL due to poor prognosis and cancer and
treatment related adverse events. Unfortunately, trials
investigating new therapies and treatment modalities in
lung cancer often assess the impact on QoL with the use
of HRQoL instruments. [2, 24–26]. This is unfortunate
as the WHOQOL-BREF may facilitate a more comprehen-
sive evaluation of QoL. Given the importance of a compre-
hensive evaluation of QoL, the present study assessed the
psychometrics and MCIDs of the WHOQOL-BREF in pa-
tients with advanced lung cancer to facilitate adequate QoL
monitoring in clinical practice and lung cancer trials. In
general, our study demonstrated that the WHOQOL-BREF
is a reliable and valid instrument in patients with advanced
lung cancer.
Table 4 Correlations of the WHOQOL-BREF with the EORTC QLQ-C30 domains (n = 153)
EORTC QLQ-C30 domains/Items WHOQOL-BREF domains/items
General facet Physical Health Psychological Health Social Relationships Environment
Physical Functioning 0.43* 0.73* 0.37* 0.04 0.26*
Role Functioning 0.46* 0.73* 0.46* 0.08 0.26*
Emotional Functioning 0.49* 0.51* 0.61* 0.19** 0.43*
Cognitive Functioning 0.33* 0.49* 0.47* 0.08 0.40*
Social Functioning 0.42* 0.59* 0.47* 0.07 0.32*
Global Health Status/QoL 0.67* 0.73* 0.58* 0.12 0.39*
Fatigue − 0.39* − 0.69* − 0.44* − 0.06 −0.33*
Nausea and vomiting −0.32* − 0.29* − 0.24* − 0.16 −0.05
Pain −0.32* − 0.62* − 0.28* − 0.06 −0.26*
Dyspnoea − 0.28* − 0.30* − 0.15 0.05 −0.10
Insomnia −0.29* − 0.49* − 0.35* − 0.04 −0.32*
Appetite loss − 0.36* − 0.38* − 0.22* 0.02 −0.05
Constipation −0.17** − 0.23* − 0.18** − 0.06 −0.24*
Diarrhea 0.00 −0.08 − 0.04 −0.10 − 0.06
Financial problems −0.03 − 0.34* − 0.22* − 0.11 −0.36*
Pearson correlation coefficients
*P < 0.01
**P < 0.05
Abbreviations: WHOQOL-BREF World Health Organization Quality of Life-BREF questionnaire, EORTC QLQ-C30 European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Core 30, n number of patients, QoL quality of life
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Facet was more positively skewed in our study compared
with the WHOQOL-BREF field trial reflecting higher
frequencies of patients with worse general health [5].
This is as expected given the frequent occurrence of ad-
verse events and poor prognosis of advanced lung can-
cer. However, the patients in this study indicated better
QoL for several items of the Psychological Health, Social
Relationships and Environment domains than the pa-
tients included in the field trial. Moreover, an additional
seven items of these three domains were negatively
skewed in our patients indicating also better QoL. One
item (i.e. Negative Feelings) was positively skewed dem-
onstrating that most patients rarely experienced negative
feelings while the WHOQOL-BREF field trial observed
higher frequencies in the scale points that corresponded
with increased negative feelings. As this higher level of
QoL was not related to physical QoL, which is in general
determined by universal factors (i.e. the cancer and its
treatment), but rather to the other domains of the
WHOQOL-BREF, this may be explained by several rea-
sons. Given the negative skewness of seven of the eight
items of the Environment domain, it is likely that the
high standard of care and the high level of prosperity in
the Netherlands may be, at least in part, responsible for
this observation. In addition, patients with lung cancer
may experience less psychological distress compared topatients with other types of cancer. A meta-analysis by
Krebber et al. found that the prevalence of depression as
diagnosed by a structural interview was the lowest (3%)
in lung cancer patients compared with other forms of
cancer. The prevalence of depression as diagnosed by
self-report instruments (20%) was also lower or compar-
able with other forms of cancer [27].
Prior to testing the reliability and validity of the
WHOQOL-BREF, we performed a first order CFA to
analyse if the proposed four factor model matched with
the patients in the present study. Before (i.e. RMSEA)
and after (i.e. CFI and RMSEA) adding error covariances
between the measurement errors of items Pain and
Medication and between items Positive Feelings and
Spirituality, the observed fit indices indicated a slightly
better model fit than the field trial of the WHOQOL-
BREF [5]. However, as we were not able to calculate 95%
confidence intervals for the observed fit indices and Ske-
vington et al. did not report them [5], we could not de-
termine if the CFI and RMSEA observed in the present
study were significantly different. Moreover, if they are
different, it is likely that the differences in fit indices are
explained by the differences between patient populations
of both studies. In the present study a homogeneous sam-
ple of patients with advanced disease lung cancer was used
whereas the patient population of the WHOQOL-BREF
field trial consisted of patients with different diseases [5].
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Table 6 Estimates of minimal clinically important differences on
WHOQOL-BREF domains
Domains 0.5 SD 1 SEM
General Facet 0.876
Physical Health 1.545 2.155
Psychological Health 1.259 1.914
Social Relationships 1.274 2.716
Environment 1.142 1.761
Abbreviations: WHOQOL-BREF World Health Organization Quality of Life
questionnaire, SD standard deviation, SEM standard error of measure
de Mol et al. BMC Cancer         (2018) 18:1173 Page 10 of 12Also the statistical differences between the present study
and that of Skevington et al. impair the direct comparison
of model fit.
Similarly as observed by Skevington et al., the internal
consistency of the Social Relationships domain was
below the commonly accepted value of 0.7 [5] whereas
the other domains all had a Cronbach’s alpha > 0.70. As
Cronbach’s alpha is in part dependent of the number of
items of a domain, a reason for this low alpha possibly
lies in the fact that the Social Relationships domain con-
sists of just three items. In a recent Taiwanese validation
study of the WHOQOL-BREF which did not report spe-
cific results of patients with advanced disease lung can-
cer (i.e. overall results of Rasch analyses of patients with
stage I to IV disease were reported), the inclusion of one
extra item (i.e. Being Respected) in the Social Relation-
ship domain resulted in a Cronbach’s alpha of 0.67 [12],
which is higher than observed in this study, although
comparable with the alpha found in the field trial (0.68)
[5]. Explanations for the lower observed internal
consistency of the Social Relationships domain in our
study in contrast with the other two reports could be
the homogeneity of the patient sample or the decreased
ability of the combined items to reflect the underlying
construct in patients with advanced disease lung cancer
compared to those with limited disease stage or other
forms of cancer or chronic diseases. Furthermore, one
of the three items (i.e. Personal Relations) had a higher
correlation with the Environment domain than with its
own hypothesized domain in this study which indicates
that this item may not be completely representative for
the construct of Social Relationships. In addition to the
relatively low Cronbach’s alpha, this result further ham-
pers the interpretation of analyses with this domain and
raises the question if the three items should be assessed
separately.
After performing multi-trait/multi-item analyses we
observed similar cross domain correlations as the field
trial did. While the Self-esteem item of the Psychological
Health domain in the field trial was strongly related with
the other three domains [5], we observed a stronger cor-
relation with the Physical Health domain than with itsown domain. This is not only in contrast with the results
of the field trial [5], but also with patients with other
forms of cancers. One study in cervical cancer survivors
reported that self-esteem was related to the mental com-
ponent summary score and not with the physical com-
ponent summary score of the Short Form 36 QoL
questionnaire [28]. A reason for this result could be the
considerable impact advanced lung cancer can have on
physical abilities. This may lead to dependence of others
which could affect self-esteem. In the field trial of the
WHOQOL-BREF the centre specific analyses revealed
that the items Safety & Security and Energy often had
higher correlations with domains other than their own
[5] whereas we found that this was the case for the items
Sleep, Body Image, Self-esteem, and Personal Relations.
These differences in cross-correlation could be explained
by some reasons. For instance, as the sample size of this
study was relatively small, the observed differences may
reflect mere chance than a true observation. Also meth-
odological differences and the specific characteristics of
patients with advanced disease (e.g. poor prognosis,
prone to cancer related adverse events) are, at least in
part, responsible for these findings.
In general, low correlations were observed between
WHOQOL-BREF domains and EORTC QLQ-C30
domains/ symptom scales. This is probably related to
differences in constructs and concepts between the
questionnaires. Whereas the WHOQOL-BREF is a
generic questionnaire, the EORTC QLQ-C30 is a can-
cer specific questionnaire. Moreover, items of the
WHOQOL-BREF are positively phrased while those of
the EORTC QLQ-C30 are often negatively phrased. In
this regard, the EORTC QLQ-C30 may not be
regarded as a gold standard to evaluate construct
validity of the WHOQOL-BREF. In addition, this also
points to the additional value of the WHOQOL-BREF
in QoL analyses in cancer patients.
Both the field trial of the WHOQOL-BREF and the re-
cent Taiwanese study did not report MCIDs to facilitate
the clinical application of the WHOQOL-BREF [5, 12].
In the present study, we were able to report statistically
derived MCIDs for the four WHOQOL-BREF domains.
Because we were not able to perform a test-retest reli-
ability analysis, we used the conservative lower bound of
the 95% confidence intervals of each of the Cronbach’s
alphas of the WHOQOL-BREF domains for the calcula-
tion of the 1 SEM MCIDs. Considering the vulnerability
of patients with advanced lung cancer for treatment and
cancer related adverse events and the short period of 3
weeks between chemotherapy cycles, we expected it to
be difficult to define an appropriated interval between
completions of the WHOQOL-BREF for two reasons. 1)
If the interval between completions of the WHOQOL-
BREF would be too short, patients could recall their
de Mol et al. BMC Cancer         (2018) 18:1173 Page 11 of 12earlier answers. 2) If the interval between completions of
the WHOQOL-BREF would be too long, it is likely that
the occurrence of therapy and cancer related adverse
events would have biased WHOQOL-BREF scores.
However, by taking the lower bound of the confidence
interval, we expected that patients who experience a
larger difference over time than the observed SEM
estimates are likely to have a true change. Considering
that the 0.5 SD MICDs depend on the variance of test
scores, which are expected to be relatively small in a
homogenous patient population as in the present study,
the larger 1 SEM MCIDs may provide a more conserva-
tive method for the interpretation of individual scores.
However, 1 SEM MCIDs depend on the reliability of a
questionnaire. A questionnaire with a limited reliability
may result in a relatively large 1 SEM. This could result
in an overestimation of the true MCID which decreases
sensitivity. Given these considerations, we calculated
MCIDs according to both methods and recommended
to base the choice for either of the two approaches on
the homogeneity of the patient sample and the reliability
of the questionnaire in the particular population.
Another limitation is that the present study used CFA
in combination with the multi-trait/multi-method meth-
odology [14, 15] which is in contrast with the increased
application of Rasch analysis in recent years to assess
psychometric properties of QoL questionnaires in cancer
[29–32]. However, we chose the same methodology for the
analyses to enable precise comparisons of the psychometric
properties observed in this study with those reported by the
original field trial of the WHOQOL-BREF.
Lastly, the sample size of our study could be consid-
ered a limitation. Although we included less than recom-
mended 200 patients by Boomsma and Hoogland [33],
we still observed an acceptable model fit which demon-
strated that our data suited the simple design of the
model [34].Conclusions
This study demonstrated that the WHOQOL-BREF has
satisfactory reliability and validity in patients diagnosed
with advanced disease lung cancer. Moreover, we identi-
fied and proposed MCIDs to facilitate application of the
WHOQOL-BREF not only in studies investigating new
therapies and treatment modalities, but also in daily
clinical practice.
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